ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2615

Serum Beta 2 Microglobulin and Its Association With Disease Activity in Patients With Behcet’s Disease

Meltem Alkan Melikoglu1 and Mehmet Melikoglu2, 1Rheumatology, Ataturk University Faculty of Medicine, Erzurum, Turkey, 2Dermatology, Health Ministry Erzurum Regional Training and Research Hospital, Dermatology, Erzurum, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose: β2-microglobulin (β2M) is a low-molecular weight protein, that is a constant component of human leukocyte antigen (HLA), which is secreted from all nucleated cells. Serum β2M levels increase in lymphoproliferative and autoimmune diseases related to the activities of B lymphocytes (1). The number of B cells secreting immunoglobulins increased in the active phase of Behçet’s disease (2). The aim of this study was to evaluate a possible relation between B2M and Behcet’s Disease (BD) clinical disease activity.

Methods:

Seventy eight patients with BD were included in our study. Disease activity was evaluated with “BD Current Activity Form” (BDCAF) which offers an easy-to-complete, valid and reliable method of assessing disease activity in BD. With this activity form, headache, mouth ulceration, genital ulceration, erythema, skin pustules, arthralgia, arthritis, new involvements in gastrointestinal system (GIS), eye, nervous system, major vessels and patient’-physician’s assessments of the overall disease activity scores were analyzed. The levels of serum B2M of the patients were also measured. The independent samples t test and Pearson’s correlation test were used to analyze the data.

Results:

In the comparison of serum B2M levels of the patients with or without the components of BDCAF, no significant relation could be found between headache, mouth ulceration, genital ulceration, erythema nodosum, superficial thrombophlebitis, skin pustules, arthralgia, arthritis, new involvements in gastrointestinal system (GIS), nervous system, major vessels and patient’-physician’s overall perception of disease activity. However, we found significantly higher levels of B2M in patients with uveitis than without eye involvement (p=0,032). Although each component of BDCAF did not show an association with B2M levels except from eye involvement, total BDCAF score was also found to be correlated with B2M levels (p˂0,05).

Conclusion:

Presence of a new developed eye involvement may be associated with higher levels B2M. Correlation between total disease activity score and B2M levels may contribute the overall disease activity perception in BD.


Disclosure:

M. A. Melikoglu,
None;

M. Melikoglu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-beta-2-microglobulin-and-its-association-with-disease-activity-in-patients-with-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology